NCT01129648View on ClinicalTrials.gov

Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Gout
Interventions
DRUG

Placebo

Administered daily for 21 days

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

BCX4208

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

BCX4208

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

BCX4208

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

Allopurinol

Administered daily for 21 days.

DRUG

BCX4208

Adminstered daily for 21 days

Trial Locations (18)

16635

Duncansville

21702

Frederick

27609

Raleigh

28211

Charlotte

33143

South Miami

37620

Bristol

38654

Olive Branch

40504

Lexington

57702

Rapid City

59107

Billings

68134

Omaha

75235

Dallas

83704

Boise

85251

Scottsdale

87106

Albuquerque

89502

Reno

92618

Irvine

96814

Honolulu

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY